YD Bio Limited (NASDAQ:YDES) Sees Significant Increase in Short Interest

YD Bio Limited (NASDAQ:YDES) was the target of a significant growth in short interest during the month of September. As of September 15th, there was short interest totaling 42,960 shares, a growth of 223.2% from the August 31st total of 13,293 shares. Approximately 0.1% of the company’s stock are sold short. Based on an average daily trading volume, of 619,936 shares, the short-interest ratio is presently 0.1 days.

Institutional Investors Weigh In On YD Bio

A hedge fund recently raised its stake in YD Bio stock. Cypress Capital Management LLC WY grew its position in shares of YD Bio Limited (NASDAQ:YDES) by 9.8% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 33,690 shares of the biotechnology company’s stock after buying an additional 3,000 shares during the quarter. Cypress Capital Management LLC WY’s holdings in YD Bio were worth $76,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

YD Bio Stock Up 20.1%

YD Bio stock opened at $5.73 on Friday. YD Bio has a one year low of $1.70 and a one year high of $22.00. The business’s fifty day moving average is $3.32 and its 200 day moving average is $4.19.

YD Bio (NASDAQ:YDES) last announced its quarterly earnings results on Tuesday, September 1st. The biotechnology company reported $0.05 earnings per share (EPS) for the quarter. The company had revenue of $0.42 million for the quarter.

Wall Street Analyst Weigh In

Separately, Wall Street Zen upgraded shares of YD Bio to a “hold” rating in a report on Saturday. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has an average rating of “Sell”.

About YD Bio

YD Bio Limited is a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations.